Cough in Idiopathic Pulmonary Fibrosis (IPF) Market Outlook, Trends And Future Opportunities (2024-2031)

Download FREE Sample Customize As Per Need Buy Now
  1. home
  2. Report Store
  3. Cough in Idiopathic Pulmonary Fibrosis (IPF) Market

Cough in Idiopathic Pulmonary Fibrosis (IPF) Market Outlook, Trends And Future Opportunities (2024-2031)

Cough in Idiopathic Pulmonary Fibrosis (IPF) Market, By Drug Class (Anti-fibrotic agents, Immunosuppressants, Corticosteroids, Antioxidants, Others (Mucolytics, Bronchodilators)), By Route of Administration (Oral, Inhalation, Intravenous, Others (Subcutaneous, Intramuscular)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others (Specialty Pharmacies, Mail Order Pharmacies)), By Disease Subtype (Idiopathic Pulmonary Fibrosis (IPF), Non-IPF Interstitial Lung Diseases (ILDs), Acute Interstitial Pneumonitis, Chronic Hypersensitivity Pneumonitis, Others (Cryptogenic Organizing Pneumonia, Sarcoidosis)), By End-User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Care Settings, Others (Research Institutes, Academic Institutions)), By Mechanism of Action (Tyrosine Kinase Inhibitors, Antioxidants, Anti-inflammatory Agents, Immunosuppressants, Others (Mucolytics, Bronchodilators)), Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) The report offers a comprehensive view of the market from supply as well as demand side to help take informed decisions.

  • Published On: Apr 2024
  • Author(s): Sagar Karlekar
  • Report ID: IDA101
  • Region: Global
  • Format: PDF/EXCEL
Press Release: Cough in Idiopathic Pulmonary Fibrosis (IPF) Market is Forecasted to Hit US$ 6.2 Bn By 2031 | CAGR 8.7%

Table Of Contents:

Chapter 1. Research Methodology and Scope

  • Market Segmentation and Scope
  • Regional Coverage
  • Objectives
  • Research Methodology

Chapter 2. Executive Summary

  • Market Landscape
  • Market Size & Forecast
  • Competitive Landscape

Chapter 3. Cough in Idiopathic Pulmonary Fibrosis (IPF) Market: Drug Class Segment Trends, Size, and Future Outlook

  • Drug Class Segment Market Size (US$), CAGR (%), and Forecast (2021-2031)
  • Drug Class Segment Definitions, Technology Landscape
  • Drug Class Segment Market Drivers
    • Product Launches
    • Technology Launches
  • Drug Class Segment Market Restraints

Chapter 4. Cough in Idiopathic Pulmonary Fibrosis (IPF) Market: Route of Administration Segment Trends, Size, and Future Outlook

  • Route of Administration Segment Market Size (US$), CAGR (%), and Forecast (2021-2031)
  • Route of Administration Segment Definitions, Technology Landscape
  • Route of Administration Segment Market Drivers
    • Product Launches
    • Technology Launches
  • Route of Administration Segment Market Restraints

Chapter 5. Cough in Idiopathic Pulmonary Fibrosis (IPF) Market: Distribution Channel Segment Trends, Size, and Future Outlook

  • Distribution Channel Segment Market Size (US$), CAGR (%), and Forecast (2021-2031)
  • Distribution Channel Segment Definitions, Technology Landscape
  • Distribution Channel Segment Market Drivers
    • Product Launches
    • Technology Launches
  • Distribution Channel Segment Market Restraints

Chapter 6. Cough in Idiopathic Pulmonary Fibrosis (IPF) Market: Disease Subtype Segment Trends, Size, and Future Outlook

  • Disease Subtype Segment Market Size (US$), CAGR (%), and Forecast (2021-2031)
  • Disease Subtype Segment Definitions, Technology Landscape
  • Disease Subtype Segment Market Drivers
    • Product Launches
    • Technology Launches
  • Disease Subtype Segment Market Restraints

Chapter 7. Cough in Idiopathic Pulmonary Fibrosis (IPF) Market: End-User Segment Trends, Size, and Future Outlook

  • End-User Segment Market Size (US$), CAGR (%), and Forecast (2021-2031)
  • End-User Segment Definitions, Technology Landscape
  • End-User Segment Market Drivers
    • Product Launches
    • Technology Launches
  • End-User Segment Market Restraints

Chapter 8. Cough in Idiopathic Pulmonary Fibrosis (IPF) Market: Mechanism of Action Segment Trends, Size, and Future Outlook

  • Mechanism of Action Segment Market Size (US$), CAGR (%), and Forecast (2021-2031)
  • Mechanism of Action Segment Definitions, Technology Landscape
  • Mechanism of Action Segment Market Drivers
    • Product Launches
    • Technology Launches
  • Mechanism of Action Segment Market Restraints

Chapter 9. Cough in Idiopathic Pulmonary Fibrosis (IPF) Market: Regional Market Trends, Size, and Future Outlook

  • North America
    • Trends, Market Size (US$), CAGR (%), and Future Outlook
      • Market Size (US$), CAGR (%), and Forecast (2021-2031)
      • Definitions, Technology Landscape
      • Market Drivers
        • Product Launches
        • Technology Launches
      • Market Restraints
      • Competitive Outlook
  • Europe
    • Trends, Market Size (US$), CAGR (%), and Future Outlook
      • Market Size (US$), CAGR (%), and Forecast (2021-2031)
      • Definitions, Technology Landscape
      • Market Drivers
        • Product Launches
        • Technology Launches
      • Market Restraints
      • Competitive Outlook
  • Asia Pacific
    • Trends, Market Size (US$), CAGR (%), and Future Outlook
      • Market Size (US$), CAGR (%), and Forecast (2021-2031)
      • Definitions, Technology Landscape
      • Market Drivers
        • Product Launches
        • Technology Launches
      • Market Restraints
      • Competitive Outlook
  • Latin America
    • Trends, Market Size (US$), CAGR (%), and Future Outlook
      • Market Size (US$), CAGR (%), and Forecast (2021-2031)
      • Definitions, Technology Landscape
      • Market Drivers
        • Product Launches
        • Technology Launches
      • Market Restraints
      • Competitive Outlook
  • Middle East, and Africa
    • Trends, Market Size (US$), CAGR (%), and Future Outlook
      • Market Size (US$), CAGR (%), and Forecast (2021-2031)
      • Definitions, Technology Landscape
      • Market Drivers
        • Product Launches
        • Technology Launches
      • Market Restraints
      • Competitive Outlook

Chapter 10. Cough in Idiopathic Pulmonary Fibrosis (IPF) Market: Competitive Landscape

  • Roche
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Boehringer Ingelheim
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Genentech
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Fibrogen
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Prometic Life Sciences
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Galapagos
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Biogen
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Promedior
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Gilead Sciences
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Kadmon Holdings
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Bristol-Myers Squibb
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Vertex Pharmaceuticals
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Bayer
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Sanofi
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Merck
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • AstraZeneca
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Novartis
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • GlaxoSmithKline
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Pfizer
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Johnson & Johnson
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Research Methodology
    • Primary Research
    • Secondary Research
    • Assumptions
    • IDataAcumen Analysis
    • Paid Databases
  • Appendix
    • About Us

Frequently Asked Questions

The current market size of the Cough in Idiopathic Pulmonary Fibrosis (IPF) industry is US$ 3.2 billion.

Increasing prevalence of IPF, aging population, environmental exposures, genetic predisposition, improved diagnostics, rising healthcare expenditure, and availability of advanced treatments.

Limited treatment options, high treatment costs, side effects of medications, lack of awareness, and challenges in early diagnosis.

The leading component segment in the Cough in Idiopathic Pulmonary Fibrosis (IPF) Market is the anti-fibrotic agents segment, used to slow disease progression.

Roche, Boehringer Ingelheim, Genentech, Fibrogen, Prometic Life Sciences, Galapagos, Biogen, Promedior, Gilead Sciences, and Kadmon Holdings.

The North American region is expected to lead the Cough in Idiopathic Pulmonary Fibrosis (IPF) Market, with a projected CAGR of 8.7% and a market size of US$ 6.2 billion by 2031.

Increasing prevalence of IPF, aging population, environmental exposures, genetic predisposition, improved diagnostics, rising healthcare expenditure, and availability of advanced treatments.
Download FREE Sample Buy Now